Validation of real-time reverse transcription polymerase chain reaction to detect virus titer and thermostability of Newcastle disease live virus vaccine

Pangkaj Kumar Dhar, Avijit Dutta, Avijit Das, Mohammad Shah Jalal, Himel Barua and Paritosh Kumar Biswas

Department of Microbiology and Veterinary Public Health, Chittagong Veterinary and Animal Sciences University, Khulshi, Chittagong-4225, Bangladesh.

Corresponding author: Pangkaj Kumar Dhar, e-mail: pangkaj23@gmail.com
Co-authors: ADu: avijitduttaavm@gmail.com, ADA: vdr.avijit@gmail.com, MSJ: shah.jalal.baty@gmail.com, HB: himel.barua@gmail.com, PKB: biswaspk2000@yahoo.com

Received: 15-03-2018, Accepted: 09-10-2018, Published online: 20-11-2018

doi: 10.14202/vetworld.2018.1597-1603 How to cite this article: Dhar PK, Dutta A, Das A, Jalal MS, Barua H, Biswas PK (2018) Validation of real-time reverse transcription polymerase chain reaction to detect virus titer and thermostability of Newcastle disease live virus vaccine, Veterinary World, 11(11): 1597-1603.

Abstract

Background and Aim: Newcastle disease is one of the most common diseases affecting poultry in Bangladesh. The disease can cause up to 100% mortality but is preventable if birds are timely and properly vaccinated with a vaccine of standard virus titer. Different live vaccines are commercially available in the country - most, if not all, are produced using lentogenic strains of the virus with variable virulence. One of the disadvantages of these vaccines is that they are not stable at high environmental temperature, and therefore, a proper cold chain must be maintained during transportation and storage. Information on how long these vaccine viruses can withstand environmental temperature, which is near the vicinity of 37°C in the summer season in Bangladesh, is scanty. The aim of this research was to measure the effect of temperature on virus titer of live ND virus vaccines and to develop a real-time reverse transcription polymerase chain reaction (rRT-PCR) standard curve to indirectly determine hemagglutination (HA) titer of virus by this highly sensitive method.

Materials and Methods: In this study, thermostability of five commercial live vaccines containing LaSota, F,Clone 30, and B1 type LaSota strains was observed for up to 35 days keeping them at 37°C. From the most thermostability yielding sample, two rRT-PCR standard curves were developed: (1) By plotting the cycle threshold (C_{T}) values as obtained from 10-fold serial dilutions up to 10^{-1} against their corresponding log (to the base 10) dilutions and (2) by plotting the C_{T} values obtained from serial HA dilutions up to 2^{-4} against their corresponding HA titer dilutions. The PCR efficiencies based on which the graphs were fitted were also evaluated.

Results: The vaccine from the LaSota strain withstood 37°C for 35 days with a gradual declination of HA titer over time, and this vaccine also had the highest initial HA titer, which was 2^{11}. The vaccine made from F strain was inactivated quickly, and it had the lowest HA titer at the beginning of the study. The first standard curve developed can be used to assess the level of virus titer in a diluted sample compared with the titer in the original undiluted vaccine preparation by plotting the C_{T} value obtained from the dilution by rRT-PCR. The second standard curve can be used to calculate the HA titer of a vaccine dilution by plotting the C_{T} value as obtained from the dilution by rRT-PCR.

Conclusion: The regression equations for the first and second graphs were y=-3.535x+14.365 and y=-1.081x+13.703, respectively, suggesting that, for every 3.53 cycles, the PCR product would have increased 10 times and 2 times for every 1.08 cycles, respectively, indicating nearly (but not exactly) 100% PCR efficiency.

Keywords: LaSota strain, Newcastle disease, real-time reverse transcription polymerase chain reaction, thermostability, vaccine, validation.

Introduction

Newcastle disease (ND) is considered as one of the most important infectious diseases of poultry due to its potential for devastating losses. It is one of the leading causes of mortality in chickens due to respiratory symptoms in poultry that occurs worldwide [1,2]. It affects respiratory, nervous, and digestive systems and shows variable symptoms depending on the strain of the virus, species of bird, concurrent disease, and preexisting immunity. ND virus (NDV) is the causal agent of ND and is a member of the genus Avulavirus [3,4] in Paramyxoviridae family. NDV is an enveloped virus which consists of a negative-sense, single-stranded, non-segmented, RNA genome. It is also known as avian paramyxovirus 1 (APMV-1) [5]. Based on pathogenicity in chicken, there are three pathotypes or strains of NDV have been identified, namely highly virulent (velogenic), intermediate (mesogenic), or avirulent (lentogenic) [6]. NDV genome is composed of six genes, and their corresponding six structural proteins are nucleoprotein (NP), phosphoprotein (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN), and RNA polymerase (L) [7]. Among them, only the HN and F
glycoproteins, important for binding and fusion of the virus to host cells, are known to induce neutralizing antibodies after vaccination that confers protection from morbidity and mortality associated with virulent NDV infection [8-10]. Infection by velogenic strain may cause 80-90% mortality in adult birds [11]. The severity of the disease varies greatly, spanning from peracute case with almost 100% mortality to subclinical with no lesions [12,13].

Vaccination is the most successful tool for the prevention of ND. Improper vaccination may result in the outbreak of ND in chicken [14,15]. All the NDV viruses belong to APMV-1 viruses; therefore, by definition, any NDV vaccine strain should provide protection against morbidity and mortality from any NDV challenge virus [16]. The efficacy of a live vaccine administered is significantly dependent on the virus titer in the vaccine [17,18]. Environmental temperature has a negative impact on persisting live virus titer [19]. Thus, maintaining the cooling chain during transportation and storage of a ND vaccine is a prerequisite for a satisfactory immune response while administered in poultry [20].

However, very little is known on the degree of thermostability and effect on environmental temperature on virus strains used as live ND vaccines in Bangladesh. The titer of virus in a vaccine can be roughly assessed by hemagglutination (HA) test [17,21] but can more reliably be estimated with other highly sensitive testing, such as reverse transcription polymerase chain reaction (rRT-PCR) [22]. To make a relationship between these two tests, validation is required to develop rRT-PCR standard curve to measure the level of virus titer in terms of HA unit in a live vaccine suspension.

The aim of this research was to measure the effect of temperature on virus titer of live ND virus vaccines and to develop a real-time reverse transcription polymerase chain reaction (rRT-PCR) standard curve to indirectly determine hemagglutination (HA) titer of virus by this highly sensitive method.

**Materials and Methods**

**Ethical approval**

Experiment was not done on any living animal, so, no ethical approval was required.

**Samples**

Five ND live virus vaccines from different lentogenic strains available commercially in Bangladesh were chosen for the present study. The vaccines were collected from local pharmaceutical shops except sample 1, which was from the Department of Livestock Service, Bangladesh. All the vaccines were carried in ice boxes and stored at 4°C in the laboratory until the experimentation begins. Before further testing of the vaccines, all the vaccines were prepared according to the manufacturer guidelines. 500 doses of vaccines were mixed thoroughly with 1.5 ml of distilled water, and 1000 doses of vaccines were mixed with 3 ml of distilled water just before the experimentation.

**Plate HA test**

To check the thermostability of the vaccines, all the samples were run for plate HA test, repeatedly, using 1% chicken red blood cells collected from specific pathogen-free flock [23]. The test was operated on 1st, 2nd, and 3rd days consecutively and then followed on every 7th day until the titer downgraded to nil. After the test on 1st day, vaccines were kept in an incubator at 37°C until the end of the test. Three different batches of the vaccines were tested with the same procedure in three different times.

**Determination of thermostability**

Result obtained from every test was recorded in a table and thermostability of the vaccines was determined by calculating the rate of downgrading of the HA titer. The vaccine that showed the longest period of thermostability in the initial experiment was chosen to develop an rRT-PCR standard curve to determine HA titer of a live ND vaccine by performing rRT-PCR.

**Vaccine selection for rRT-PCR**

Vaccine sample that showed the longest period of thermostability at 37°C was used for real-time PCR experiment. The PCR was based on a 150 bp, conserved region of the APMV-1 L polymerase gene, in which two probes were included, as per the protocol followed at the UK Animal and Plant Health Agency. Two serial dilutions of the vaccine were made: 10-fold and 2-fold. 10-fold serial dilution was made up to $10^{-3}$ and 2-fold up to $2^{-4}$. From each of 10-fold diluted sample, the sample was tested once for detecting the cycle threshold ($C_\text{t}$) value, while each 2-fold dilution was tested twice to calculate the mean $C_\text{t}$ value.

**Primers and probes**

Two different sets of primer and probes designed for the amplification of RNA polymerase (L) gene were used in rRT-PCR (Table-1) [24].

**Preparation of 10-fold and 2-fold dilution**

First, 10-fold serial dilution was prepared by adding 100 µl of parent vaccine sample with 900 µl of phosphate-buffered saline (PBS) to make 1000 µl of

| Table-1: PCR primer and probe sequences used to detect L gene of APMV-1 [24]. |
|---------------------------|---------------------------|
| Primer/Probes             | Sequence (5’-3’)           |
| Forward primer            | GAG CTA ATG AAC ATT CTT TC |
| Reverse primer            | AAT AGG CGG ACC ACA TC TG |
| LproMGB                   | [6FAM] CCA ATC AAC TTC CC [MGBNFQ] |
| LproMGB2                  | [VIC] AAT AGT GTA TGA CAA CAC [MGBNFQ] |

PCR=Polymerase chain reaction, APMV-1=Avian paramyxovirus 1
first 10-fold (10⁻¹) dilution. Following the same way, 10⁻² and 10⁻³ fold dilutions were prepared. In case of 2-fold dilution, 500 µl of vaccine samples were added to 500 µl of PBS, and in the same way, it was repeated to make 2⁻¹, 2⁻², 2⁻³, and 2⁻⁴ fold dilutions. Counting two from each dilution, a total of eight samples were chosen for final rRT-PCR.

**Extraction of RNA and rRT-PCR**

RNA was extracted with the RNase kit (MagMax™-96 Viral RNA Isolation Kit) using the protocol supplied by Ambion Inc. on automatic device Thermo Fisher mL (Thermo Scientific). The extracted RNAs were collected and transferred into sterile Eppendorf tubes as viral RNA extracts and preserved at −20°C until used.

The final amplification process was performed in Thermo Cycler (Applied Biosystems 7500 Fast rPCR system, Foster City, California, USA) in Micro AMP Fast Optical 96-well reaction plate. The components of master mix per 20 µl for this reaction was (for L gene), Molecular grade water (i.e., RNase-free) 2.75 µl, Qiagen QuantiFast Probe RT PCR buffer mix (w/o ROX) 12.5 µl, 68 µl ROX to 1.7 ml QuantiFast Probe RT PCR buffer mix (400 rxn kit) 0.5 µl, NDF (12.5 µM in molecular grade water) 1 µl, NDR (12.5 µM in molecular grade water) 1 µl, LproMGB (5 µM in TE buffer) 1 µl, LproMGB 2 (5 µM in TE buffer) 1 µl, Qiagen QuantiFast RT PCR enzyme mix 0.25 µl. The cycling conditions for this test were as follows: Stage 1 - 50°C for 10 min, Stage 2 - 95°C for 10 s, Stage 3 (Step 1) - 95°C for 10 s, Stage 3 (Step 2) - 50°C for 30 s, and Stage 4 - 72°C for 30 s where steps 1 and 2 in Stage 3 were run for 40 cycles. Fluorescence was read at the end of the 2nd step of Stage 3, annealing step.

**Developing standard curves**

For both of the 10-fold and 2-fold dilutions of the virus samples, two different regression curves were developed using Syntax “Twoway lift yyar xvar” with statistical package STATA 11 to make visualizing a standard curve. Cₜ values obtained from the respective dilutions were plotted on the Y-axis against their corresponding log to the dilutions at the X-axis in the stated process to produce a standard curve for each dilution.

**Results**

**Overview of the vaccines**

Three batches from each of five vaccine samples have been used in this experiment. The vaccines were as follows: Sample 1: Freeze-dried culture of lentogenic F strain, Sample 2: Live freeze-dried culture of LaSota strain, Sample 3: Live freeze-dried culture of lentogenic F strain, Sample 4: Live freeze-dried culture of Clone 30 strain, and Sample 5: Live freeze-dried cultures of B1 type LaSota strain.

**HA titer and thermostability**

The persistence of HA titer was adopted as a measure of antigen stability. Initial HA titer was as high as up to 2管理中心 which gradually declined to zero with variable time (in days) (Table-2).

It is clear from Table-2 that Sample 2 has the highest initial HA titer of 2管理中心 followed by Sample 5 which showed an HA titer of maximum 2管理中心 at the beginning. Sample 4 also showed a very good initial HA titer of 2管理中心 while Samples 1 and 3 revealed an average titer of 2管理中心 and 2管理中心 respectively.

Deterioration in HA ability of the vaccine samples is unfurled in Table-2. As Sample 2 has the most HA titer, this sample also persists in showing HA activity for the longer period compared to other under 37°C incubation. Comparative thermostability of three batches from five different samples is shown in Figure-1. Vaccine from Sample 2 survived more days in incubation at the experimental temperature (37°C). Two of three batches survived up to 5 weeks

**Table-2:** HA titer summary of the vaccines.

| Batch | Sample 1 | Sample 2 | Sample 3 | Sample 4 | Sample 5 |
|-------|----------|----------|----------|----------|----------|
| Time  | BT1 | BT2 | BT3 | BT4 | BT5 | BT6 | BT7 | BT8 | BT9 | BT10 |
| Day 1 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 |
| Day 2 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 |
| Day 3 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 |
| Day 4 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 |
| Day 5 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 | 2管理中心 |

HA=Hemagglutination
and another one up to 4 weeks. Samples 3, 4, and 5 showed an almost similar fashion of thermostability. Maximum survival period of these samples was 4 weeks. On the contrary, Sample 1 found to be least survived vaccine. Though, one batch among three in Sample 1 survived till 3rd week.

**Validation of rRT-PCR standard curves**

Two standard curves were developed on the basis of amplification curve analysis data found in rRT-PCR (Figure-2). The 1st curve was prepared by plotting $C_T$ values against the log 10 dilution of the vaccine, as displayed in Figure-3. Any $C_T$ value from an unknown sample can be referred to the curve to find the level of virus diluted from the original virus titer in the vaccine. For example, if the $C_T$ value of an unknown sample is 19, it would have been diluted at about log (to the base 10) 1.3 of its original titer as measured by any scale. The second standard curve developed was with the $C_T$ values against the HA titer (Figure-4). This graph can be used to calculate the HA titer of a vaccine dilution by doing rRT-PCR. For example, if the $C_T$ value of a vaccine dilution is 16.5, the HA titer of the virus in this dilution would be around 9. The regression equations for the first and second graphs were $y=-3.535x+14.365$ and $y=-1.081x+13.703$, respectively, meaning that, for every 3.53 cycles, the PCR product would have increased slightly above 10 times (because log [to the base 10] 3.34 equals 10) for the first curve and almost double for each cycle (because $2^{1}=2$) for the 2nd curve. The PCR results thus indicate that the standard curves were fitted nearly (but not exactly) based on 100% PCR efficiency.

**Discussion**

The study was conveyed to test the thermostability of the vaccine virus under incubation temperature (37°C) and to find a relationship between HA titer and rRT-PCR. The test was also aimed to reveal how rRT-PCR can be useful in assessing the titer is replacing the time-consuming HA testing. Five commercial live vaccines were used in this experiment, and after HA test, the vaccine that was found with higher HA titer was chosen for further RT-PCR validation.

The persistence of HA titer was adopted as a measure of antigen stability. The result of the study depicted that initial HA titers of the vaccines were variable. Sample 2 had the highest titer of $2^{11}$ among these. This vaccine was made from LaSota strain. Another vaccine that was made from B1 type of LaSota strain, Sample 5, showed an HA titer of $2^{9-2^{10}}$ at the beginning. Sample 1 and 4, made of F strain, had almost the same HA titer around $2^{6}$ and $2^{7}$, respectively. The other vaccine sample made from Clone 30 strain had an initial HA titer level of $2^{9}$. The result showed that Sample 2 or LaSota strain vaccine has better HA titer than other live vaccine virus strain. Previous studies showed that 2- to 8-fold difference of HA titer was observed among live commercial Newcastle vaccine virus in Pakistan [25]. However, pre-temperature exposure titer log of LaSota and B1 strain was 26 and 25, respectively, in another experiment [21]. In Japan, different lentogenic strains of NDV were tested for HA titer activity and found the titer between $2^{6}$ and $2^{11}$ [26].

At an incubation temperature of 37°C, vaccine virus samples showed different lines of stability.
Two types of vaccine are considered thermostable: Australian V4 and I2, both are produced from live, avirulent strain [9,14]. Australia V4 had both thermostability and immunogenicity and was specifically developed to be used in village chicken. It is administered in coated pelleted feed [28].

A thermostable vaccine enables distributors and users to reduce the problems associated with inadequate cold chains in the field. Instead of that, a thermostable vaccine must still be treated with some of the respects as it is a biological product, that the vaccine being exposed to sunlight, and frequent shifts in temperature and still expect it to remain active [29]. Any break in this chain removes any guarantee of effective protection against the disease [22,30].

To check the validity of rRT-PCR in assessing the HA titer, \( C_\chi \) value achieved from the PCR and HA titer along with the dilution of the vaccine virus sample was analyzed in different ways. It is obvious that \( C_\chi \) value is inversely proportionate to the dilution of the virus. This experiment also found the same pattern. As \( C_\chi \) value increased, HA titer decreased gradually. However, validation of rRT-PCR of a virus for rapid quantification of HA titer in vaccine is not well established yet. Therefore, in this study, we tried to develop and validate an rRT-PCR method for rapid quantification of NDV in vaccine sample. The PCR method was operated based on targeting polymerase (L) gene of APMV-1 as the sensitivity of this method is much higher than other gene targeting PCR method [24].

Comparing \( C_\chi \) value against the HA titer of both 2-fold and 10-fold diluted vaccine samples, the correlation coefficients were 0.9753 and 0.9638, respectively. Hence, the \( C_\chi \) value can be 97.53% accurate to determine the virus titer during 2-fold dilution, while it is 96.38% in 10-fold.

In the case of dilution of the vaccine virus, \( C_\chi \) value can be predicted up to 99.35% accuracy from the dilution when dilution factor is 10-fold. If the dilution factor is 2-fold, then increase or decrease of the threshold or \( C_\chi \) value of the virus sample can be assumed with appropriateness of 97.76%. A \( C_\chi \) value as obtained from rRT-PCR could be the reflection of the titer including live viruses plus intact RNA from inactivated virus if remained present at all. It was difficult to differentiate them by rRT-PCR. However, plotting \( C_\chi \) values against HA titers to the second standard curve developed could be the way to know the tentative live virus titer subtracted from the amount of intact RNA of NDV.

The most important observation was done by finding the difference of \( C_\chi \) value if the HA titer of the vaccine virus sample changed. When HA titer falls, it clearly indicates a decrease in the amount of virus in the vaccine. In this experiment, we found that HA titer was 97.41% precise against the change of the \( C_\chi \) value difference in case of 2-fold dilution, while it is 96.38% in case of 10-fold. Hence, the change of the \( C_\chi \) value of the sample can determine the virus concentration and
thus assure the validity of the vaccine. As an rRT-PCR result is based on the number of RNA of the virus present in a matrix, the result of the study would be similar to any of the lentogenic virus strains of NDV being used as a commercial ND vaccine. Results of any further studies with a mesogenic or velogenic strain would be interesting to know to verify whether such results are reproducible to the result obtained in the present study.

This rRT-PCR assay based on the L-gene has the potential to decrease the time taken to confirm the concentration of suspected virus sample, thus determining the vaccine potential with a high degree of certainty [24]. Although serological identification followed by in vivo pathogenicity testing still remains as the gold standard, RT-PCR offers a reliable tool for quick detection of NDV. This method not only takes a shorter time to produce a result but also has more accuracy, precision, specificity, and robustness [31]. Specifically, the method was suitable for the quantification of virus titer in the vaccine sample, and it is a rapid method.

Conclusion

Among five live vaccines of different strains, one that prepared from LaSota strain showed the maximum days of positive HA (up to 35 days) under incubation at 37°C. This vaccine also showed higher initial HA titer of 211. Vaccine made from F strain survived least among these all and also showed the lowest HA titer. It indicates that vaccines from different strains have variable adaptability to the temperature. Other factors may be involved in determining the titer of any live virus vaccine. However, this study would help to understand the pattern of decline in the HA titer of the vaccines. C value of the vaccine virus sample, determined by rRT-PCR, suggests that this value varies with the dilution of virus. The two rRT-PCR standard curves developed can be used to guess the level of virus titer at any dilution from its titer at the originally undiluted stage and to estimate the level of HA titer in any diluted live ND vaccine. The curves were based on nearly (but not exactly) 100% PCR efficiency. Any future study using mesogenic or velogenic strains of this virus will help better understanding the relationship between rRT-PCR and HA titer. It will aid the vaccine manufacturers as well as researchers in deciding HA titer in the shortest possible time with much more accuracy and precision.

Authors’ Contributions

PKD and PKB: Conception and design of the study, PKD, ADu, ADa, and MSI: Conducted the experiment, analyzed, and interpreted the data. PKD, HB, and PKB: Drafting and revising the manuscript critically for important intellectual content. All authors have read and approved the final manuscript.

Acknowledgments

The authors would like to thank the Director, CASR - Centre for Advanced Studies and Research, Chittagong Veterinary and Animal Sciences University (CVASU), Bangladesh for funding the research, all the members of the Department of Microbiology and Veterinary Public Health, CVASU, and all the staffs of Poultry Research and Training Centre, CVASU, for their kind cooperation.

Competing Interests

The authors declare that they have no competing interests.

References

1. Nguyen, T.D. (1991) Poultry production and Newcastle disease in Vietnam. In: Newcastle Disease in Village Chickens, Control with Thermostable Oral Vaccines. Australian Centre for International Agricultural Research, Canberra. p169-170.
2. Usman, M., Sarwar, F., Umar, S., Subhan, S., Sohail, M.L., Younus, M. and Shah, M.A. (2017) A clinical survey of viral respiratory diseases of commercial poultry in Pakistan. J. Anim. Plant Sci., 27(6): 2086-2089.
3. Abdisa, T. and Tagesu, T. (2017) Review on Newcastle disease of poultry and its public health importance. J. Vet. Sci. Technol., 8(441): 2.
4. Mayo, M.A. (2002) A summary of taxonomic changes recently approved by ICTV. Arch. Virol., 147(8): 1655-1663.
5. Alexander, D.J. (2000) Newcastle disease and other avian paramyxoviruses. Rev. Sci. Tech. Off. Int. Epiz., 19(2): 443-455.
6. Beard, C.W. and Hanson, H.P. (1984) Newcastle disease. In: Hofstad, M.S., Bames, H.J., Calnek, B.W., Reid, B.M. and Yoder, H.W., editors. Diseases of Poultry. 8th ed. Iowa State University Press, Ames, IA. p452-470.
7. El Najjar, F., Schmitt, A.P. and Dutch, R.E. (2014) Paramyxovirus glycoprotein incorporation, assembly and budding: A three-way dance for infectious particle production. Viruses, 6(8): 3019-3054.
8. Adu-Gyamfi, E., Kim, L.S., Jardetzky, T.S. and Lamb, R.A. (2016) Flexibility of the head-stalk linker domain of paramyxovirus HN glycoprotein is essential for triggering virus fusion. J. Virol., 90(20): 9172-9181.
9. Dimitrov, K.M., Afonso, C.L., Yu, Q. and Miller, P.J. (2017) Newcastle disease vaccines-a solved problem or a continuous challenge? Vet. Microbiol., 206(7): 126-136.
10. Miller, P.J. and Koeh, G. (2015) Newcastle disease. Dis. Poultry., 13: 89-138.
11. Pansota, F.M., Rizvi, F., Sharif, A., Javed, M.T., Muhammad, G., Khan, A. and Khan, M.Z. (2013) Use of hyperimmune serum for passive immunization of chicks experimentally infected with Newcastle disease virus. Pak. J. Agri. Sci., 50(2): 279-288.
12. Orsi, M.A., DorettoJúnior, L., Reischak, D., da Silva, L.H.A., Spilki, F.R., Buzinaro, M.G. and Arns, C.W. (2009) Newcastle disease virus vaccine strains: Immunogenicity is not influenced by ICPI. Rev. Bras. Cienc. Avic., 11(2): 129-133.
13. Ashraf, A. and Shah, M.S. (2014) Newcastle disease: Present status and future challenges for developing countries. Afr. J. Microbiol. Res., 8(5): 411-416.
14. Aziz-ul-Rahman, H.M., Riaz, T., Hussain, B., Yousaf, F., Saqaleen, M. and Rasool, M.H. (2017) Seroprevalence of Newcastle disease virus (NDV) in commercial and domesticated birds: Pakistan during current surge of NDV. J. Infect. Med. Biol., 4(4): 54-59.
15. Shabbir, M.Z., Malys, T., Ivanov, Y.V., Park, J., Shabbir, M.A.B., Rabbani, M., Yaqub, T. and Harvill, E.T. (2015) Microbial communities present in the lower respiratory tract of clinically healthy birds in Pakistan. Poult. Sci., 94(4): 612-620.
16. Kapczynski, D.R., Afonso, C.L. and Miller, P.J. (2013) Immune responses of poultry to Newcastle disease virus. *Dev. Comp. Immunol.*, 41(3): 447-453.

17. Black, S., Nicolay, U., Vesikari, T., Knuf, M., Giudice, G.D, Cioppa, G.D., Tsai, T., Cleemens, R. and Rappuoli, R. (2011) Hemagglutination inhibition antibody titres as a correlate of protection for inactivated influenza vaccines in children. *Pediatr. Infect. Dis. J.*, 30(12): 1081-1085.

18. Patel, M., Glass, R.I., Jiang, B., Santosham, M., Lopman, B. and Parashar, U. (2013) A systematic review of anti-rotavirus serum IgA antibody titre as a potential correlate of rotavirus vaccine efficacy. *J. Infect. Dis.*, 208(2): 284-294.

19. Riyesh, T., Balamurugan, V., Sen, A., Bhanuprakash, V., Venkatesan, G., Yadav, V. and Singh, R.K. (2011) Evaluation of efficacy of stabilizers on the thermostability of live attenuated thermo-adapted peste des petits ruminants vaccines. *Virol. Sin.*, 26(5): 324.

20. Mahood, M.S., Siddique, F., Hussain, I., Ahmad, S.I. and Rafique, A. (2014) Thermostable vaccines for Newcastle disease: A review. *World Poult. Sci. J.*, 70(4): 829-838.

21. Nsseen, M.A.S. and Adene, D.F. (2002) Thermostability of reconstituted Newcastle disease virus strains at 36°C and 176C temperature. *Afr. J. Biomed. Res.*, 5(1-2): 87-89.

22. Bensink, Z. and Spradbrow, P. (1999) Newcastle disease virus strain I2-a prospective thermostable vaccine for use in developing countries. *Vet. Microbiol.*, 68(1-2): 131-139.

23. World Health Organization. (2002) Use of Anticoagulants in Diagnostic Laboratory Investigations (WHO/DIL/LAB/99.1 Rev. 1). World Health Organization, Geneva.

24. Fuller, C.M., Brodd, L., Irvine, R.M., Alexander, D.J. and Aldous, E.W. (2010) Development of an L gene real-time reverse-transcription PCR assay for the detection of avian paramyxovirus Type-1 RNA in clinical samples. *Arch. Virol.*, 155(6): 817-823.

25. Abbas, T., Munee, M.A., Ahmed, M.D., Khan, M.A., Younus, M. and Khan, I. (2006) Comparative efficacy of five different brands of commercial Newcastle disease Lasota virus vaccines in broilers. *Pak. Vet. J.*, 26(2): 55-58.

26. Murakawa, Y., Sakaguchi, M., Soejima, K., Eriyachi, S., Takase, K., Sueyoshi, M. and Otsuki, K. (2003) Haemagglutinating activity of the lentogenic Newcastle disease virus strain MET95. *Avian Pathol.*, 32(1): 39-45.

27. Aini, I., Ibrahim, A.L. and Spradbrow, P.B. (1992). Efficacy of food pelleted Newcastle disease vaccine: Simulated village experiments. *J. Vet. Malaysia*, 4(1): 81-86.

28. Spadobrow, P.B. (1992) Newcastle Disease in Village Chicken. Control with Thermostable Oral Vaccine. Proceeding of an International Workshop, Kuala Lumpur, Malaysia. ACIAR, Canberra.

29. Alders, R.G. and Spradobrow, P.B. (2001) Controlling Newcastle Disease in Village Chickens: A field manual. Australian Centre for International Agricultural Research, Canberra.

30. Aini, I., Ibrahim, A.L. and Spradbrow, P.B. (1990) Field trials of a food-based vaccine to protect village chickens against Newcastle disease. *Res. Vet. Sci.*, 49(2): 216-219.

31. Jang, J., Hong, S.H. and Kim, I.H. (2011) Validation of a real-time RT-PCR method to quantify Newcastle disease virus (NDV) titre and comparison with other quantifiable methods. *J. Microbiol. Biotechnol.*, 21(1): 100-108.

**********